- Home
- ATOS vs CRBP Comparison
ATOS vs CRBP Comparison
Compare ATOS & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- CRBP
- Stock Information
- Founded
- ATOS 2009
- CRBP 2009
- Country
- ATOS United States
- CRBP United States
- Employees
- ATOS N/A
- CRBP N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- CRBP Health Care
- Exchange
- ATOS Nasdaq
- CRBP Nasdaq
- Market Cap
- ATOS 130.5M
- CRBP 114.8M
- IPO Year
- ATOS 2012
- CRBP N/A
- Fundamental
- Price
- ATOS $0.98
- CRBP $16.36
- Analyst Decision
- ATOS Strong Buy
- CRBP Strong Buy
- Analyst Count
- ATOS 3
- CRBP 8
- Target Price
- ATOS $6.25
- CRBP $50.57
- AVG Volume (30 Days)
- ATOS 1.3M
- CRBP 221.8K
- Earning Date
- ATOS 11-11-2025
- CRBP 11-06-2025
- Dividend Yield
- ATOS N/A
- CRBP N/A
- EPS Growth
- ATOS N/A
- CRBP N/A
- EPS
- ATOS N/A
- CRBP N/A
- Revenue
- ATOS N/A
- CRBP N/A
- Revenue This Year
- ATOS N/A
- CRBP N/A
- Revenue Next Year
- ATOS N/A
- CRBP $220.00
- P/E Ratio
- ATOS N/A
- CRBP N/A
- Revenue Growth
- ATOS N/A
- CRBP N/A
- 52 Week Low
- ATOS $0.55
- CRBP $4.64
- 52 Week High
- ATOS $1.66
- CRBP $20.77
- Technical
- Relative Strength Index (RSI)
- ATOS 57.15
- CRBP 75.90
- Support Level
- ATOS $0.86
- CRBP $15.00
- Resistance Level
- ATOS $1.29
- CRBP $16.97
- Average True Range (ATR)
- ATOS 0.08
- CRBP 1.01
- MACD
- ATOS 0.01
- CRBP 0.28
- Stochastic Oscillator
- ATOS 38.23
- CRBP 88.01
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.